HMGB1 genetic polymorphisms in oral squamous cell carcinoma and oral lichen planus patients

Oral Diseases

Volumn 21, Issue 4, 2015, Pages 536-543

  Supic, G ^a,b   Kozomara, R ^a,b   Zeljic, K ^b,c   Stanimirovic, D ^d   Magic, M ^d   Surbatovic, M ^a,b   Jovic, N ^a,b   Magic, Z ^a,b  

^a Serbia   (Serbia)

^b UNIVERSITY OF DEFENCE   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Haplotypes; High mobility group box 1; Oral lichen planus; Oral squamous cell carcinoma; Recurrence free survival; Single nucleotide polymorphisms

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; LICHEN PLANUS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HMGB1 PROTEIN; HUMANS; LICHEN PLANUS, ORAL; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84927694032     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12318     Document Type: Article

References (36)

1. Ahn MY, Kwon SM, Cheong HH et al (2012). Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J Oral Pathol Med 41: 540-546.
2. Apetoh L, Ghiringhelli F, Tesniere A et al (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059.
3. Barnard NA, Scully C, Eveson JW, Cunningham S, Porter SR (1993). Oral cancer development in patients with oral lichen planus. J Oral Pathol Med 22: 421?424.
4. Barrett JC, Fry B, Maller J, Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
5. Bustin M (1999). Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19: 5237-5246.
6. Campana L, Bosurgi L, Rovere-Querini P (2008). HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 20: 518-523.
7. Deng C, Deng G, Wang Y (2013). HMGB1 gene polymorphisms in patients with chronic hepatitis B virus infection. World J Gastroenterol 19: 5144-5149.
8. Fahmueller Y, Nagel D, Hoffmann R et al (2013). Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer 132: 2349-2358.
9. Ferrari S, Finelli P, Rocchi M, Bianchi M (1996). The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. Genomics 35: 367-371.
10. Flohr AM, Rogalla P, Meiboom M et al (2001). Variation of HMGB1 expression in breast cancer. Anticancer Res 21: 3881-3885.
11. Georgakopoulou EA, Achtari MD, Achtaris M, Foukas PG, Kotsinas A (2012). Oral lichen planus as a preneoplastic inflammatory model. J Biomed Biotechnol 2012: 759626.
12. Gonzalez-Moles MA, Scully C, Gil-Montoya JA (2008). Oral lichen planus: controversies surrounding malignant transformation. Oral Dis. 14: 229?243.
13. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA (2008). Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29: 21-32.
14. Keyel P (2014). How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. Cytokine 69: 136-145.
15. Kornblit B, Munthe-Fog L, Petersen SL, Madsen HO, Vindeløv L, Garred P (2007). The genetic variation of the human HMGB1 gene. Tissue Antigens 70: 151-156.
16. Kornblit B, Munthe-Fog L, Madsen HO, Strøm J, Vindeløv L, Garred P (2008). Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response. Crit Care 12: R83.
17. Kornblit B, Masmas T, Petersen SL et al (2010). Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 16: 239-252.
18. Kuniyasu H, Chihara Y, Takahashi T (2003). Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10: 445-448.
19. Liu Y, Xie C, Zhang X et al (2010). Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 46: 3007-3015.
20. Lo Muzio L, Mignogna MD, Favia G, Procaccini M, Testa NF, Bucci E (1998). The possible association between oral lichen planus and oral squamous cell carcinoma: a clinical evaluation on 14 cases and a review of the literature. Oral Oncol 34: 239?246.
21. Lum HK, Lee K-LD (2001). The human HMGB1 promoter is modulated by a silencer and an enhancer-containing intron. Biochim Biophys Acta 1520: 79-84.
22. Muller S, Ronfani L, Bianchi M (2004). Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255: 332-343.
23. Nagatani G, Nomoto M, Takano H et al (2001). Transcriptional activation of the human HMGB1 gene in cisplatin-resistant human cancer cells. Cancer Res 61: 1592-1597.
24. Sasahira T, Kirita T, Oue N et al (2008). High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 99: 1806-1812.
25. Scully C, Bagan JV (2009). Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis 15: 388-399.
26. Tregouet DA, Garelle V (2007). A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 23: 1038-1039.
27. Tsunoda T, Takagi T (1999). Estimating transcription factor bindability on DNA. Bioinformatics 15: 622-630.
28. Ulloa L, Messmer D (2006). High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17: 189-201.
29. Uramoto H, Izumi H, Nagatani G et al (2003). Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J 371: 301-310.
30. Wang Y, Li XP, Yin JY et al (2014). Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response. Clin Exp Pharmacol Physiol 41: 408-415.
31. Warnakulasuriya S, Johnson NW, van der Waal I (2007). Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36: 575-580.
32. Whiteside TL (2005). Immunobiology of head and neck cancer. Cancer Metastasis Rev 24: 95-105.
33. Wild C, Brandau S, Lotfi R et al (2012). HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 48: 409-416.
34. Wu D, Ding Y, Wang S, Zhang Q, Liu L (2008). Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 216: 167-175.
35. Yan W, Chang Y, Liang X et al (2012). High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastasis. Hepatology 55: 1863-1875.
36. Zeng L, Zhang A, Gu W et al (2012). Clinical relevance of single nucleotide polymorphisms of the high mobility group box 1 protein gene in patients with major trauma in southwest China. Surgery 151: 427-436.